AR-resistance evidence network that finds prostate-cancer patients and proves target engagement for AR-pathway degrader trials.

1. Specialist capital is now committed to a focused ARON clinical program, so sponsors have both budget and urgency to buy execution infrastructure instead of stretching coordinators further.
2. IND clearance and a stated Q3 2026 clinical start mean patient qualification and pharmacodynamic logistics must be solved immediately, not after the category matures.
3. Because the therapeutic claim is about overcoming resistance in AR-driven disease, the bottleneck shifts from broad awareness to molecularly precise enrollment and evidence capture.
4. Flare's decision to focus on FX-111 while keeping adjacent ARON programs alive suggests the supporting site and biomarker stack can become reusable across a growing franchise rather than one study.

Catalyst. Flare's $85 million financing, IND clearance, and Q3 2026 start date make AR-resistance patient qualification and sample logistics a current budget line rather than a future oncology tooling idea.

The startup sells a sponsor-funded operating layer for biotechs launching novel AR-pathway trials. It ingests treatment-sequence history, molecular reports, and site workflow data to flag likely AR-driven resistant patients, retrieve missing records, and assemble sponsor-ready screening packets. For enrolled patients, the product coordinates biopsy and ctDNA windows, lab routing, and completeness checks so translational teams receive consistent pharmacodynamic readouts across sites. Sponsor dashboards show which referral sources, resistance profiles, and centers convert fastest, reducing wasted screen slots and helping teams tighten inclusion strategy mid-study. Over time, the company builds a proprietary map of where AR-driven resistant patients are found, which evidence packages predict eligibility, and which sites can generate clean mechanism data under real trial constraints.

What's different. Generic trial-recruitment vendors optimize lead volume, CROs manage site operations after protocol kickoff, and molecular-testing labs return reports without owning sponsor-specific qualification logic. This company sits in the missing layer between them: it combines treatment-sequence rules, AR-resistance evidence, and pharmacodynamic sample orchestration into one workflow built for mCRPC degrader studies. Its moat grows from a proprietary dataset of which referral sources, biomarkers, and sites actually convert into enrolled patients with usable mechanism data.

Jobs to be done

flowchart LR
  Buyer[Clinical Ops Lead] --> Pain[Hidden AR-driven resistant patients and messy biomarker workflows]
  Pain --> Product[AR resistance evidence network]
  Product --> Outcome[Faster enrollment and cleaner proof-of-mechanism data]

Executive takeaways

• The sharpest wedge is not generic oncology recruitment; it is protocol-specific qualification of AR-driven resistant patients plus clean on-target evidence capture across community and academic sites.
• Timing is real because Flare has already funded and IND-cleared FX-111, but the near-term buyer universe is still narrow enough that the beachhead must stay sponsor-focused and disease-specific.
• Budget already exists inside adjacent categories such as trial enablement, molecular profiling, site analytics, and right-in-time activation, so the startup does not need to invent a new spend line from scratch.
• Competition is intense in adjacent layers—horizontal trial platforms, molecular networks, and trial-matching services—but none of the fetched incumbents owns sponsor-specific AR-resistance evidence packaging end to end.
• The largest execution risk is not model quality alone; it is getting timely access to fragmented treatment history, molecular reports, and biopsy logistics at sites that already run on manual exception handling.
• A credible year-3 outcome is a modest but meaningful portfolio of live sponsor studies; the larger venture case depends on expanding from AR-pathway trials into broader hormone-driven and transcription-factor oncology programs.

Market definition

U.S. sponsor-funded workflow software and services for biomarker-intensive advanced prostate-cancer trials, initially focused on metastatic castration-resistant disease and AR-pathway degrader studies. The wedge sits between generic recruitment tools and full CTMS/EDC suites: patient qualification, record retrieval, screening packet assembly, and serial biopsy/ctDNA evidence orchestration.

Customer and buyer

Primary users are sponsor clinical-operations, translational-medicine, and site-startup teams trying to qualify the right mCRPC patients and collect mechanism evidence on schedule. The economic buyer is usually the VP Clinical Operations or CMO at a clinical-stage oncology biotech because the problem spans enrollment risk, translational-readout quality, and board-level proof-of-concept timelines.

Buying triggers

• IND clearance and first-patient-in planning make molecular pre-screening, biopsy timing, and ctDNA evidence capture an immediate operational bottleneck rather than a future tooling idea. [1][2][24][25][27]
• mCRPC genomic-testing expectations and resistance biology force sponsors to qualify patients with more than simple diagnosis codes or referral lists. [23][25][26][36][37]
• Persistently low oncology-trial participation and manual screening workflows create urgency for more structured site- and patient-identification processes. [28][29][31][33][34]

Willingness to pay

Willingness to pay is credible because buyers already purchase adjacent services that map directly onto the proposed wedge: trial enablement, site selection, recruitment support, molecular profiling, clinical-trial navigation, and governed oncology data operations. If the startup can measurably raise screen-pass rates or biomarker-packet completeness, it can reallocate from existing trial-operations budgets instead of asking for speculative AI spend. [12][15][20][21]

Category dynamics

Growth signal 3.0% annual U.S. prostate-cancer incidence growth (2014-2022); the niche workflow layer likely grows faster but is not directly measured

Validation signals

• Flare has already converted the ARON thesis into financed, IND-cleared clinical execution with a stated Q3 2026 start.
• Caris publicly markets rapid biomarker-linked trial matching and local activation, validating buyer demand for this adjacent operational problem.
• Incumbents market site ranking, oncology workflow, and trial-analytics tooling, confirming that sponsors and sites already budget for execution infrastructure.
• Guidelines and recent peer-reviewed work show that genomic testing, ctDNA, and pathology workflows are central to modern metastatic-prostate trial qualification and evidence capture.

Regulatory & technical constraints

• Electronic workflows used in clinical investigations need trustworthy records, signatures, and auditability acceptable to sponsor QA and FDA expectations.
• mCRPC biopsy interpretation is complicated by lineage plasticity and potential neuroendocrine transformation, which raises the bar for pathology workflow standardization.
• Liquid profiling is valuable but not universally sufficient; tissue reflex and careful interpretation remain important for many advanced-cancer workflows.

Competition is fragmented across five layers: horizontal trial platforms, site-analytics and eSource vendors, molecular-profiling and companion-diagnostic companies, right-in-time trial networks, and broad patient-matching/referral services. The white space is a sponsor-owned AR-resistance evidence layer that works across heterogeneous records and emphasizes mechanism-data completeness, not just patient lead generation.

Why incumbents do not win by default

• Horizontal trial platforms. Medidata-class platforms are strong at governed workflows, site analytics, and data quality, but they do not win by default at protocol-specific AR-resistance qualification and biopsy-window orchestration.
• Molecular profiling and trial networks. Caris- and Foundation-class incumbents own valuable testing and trial-matching infrastructure, yet their default posture centers on their own profiling network rather than a sponsor-specific evidence packet assembled across mixed data sources.
• Site- and patient-experience tooling. Clinical Ink-class tools improve regulated data capture and adherence visibility, but they sit farther downstream than the initial patient-finding and qualification problem.
• Broad matching and referral services. MassiveBio-class services broaden top-of-funnel access, but the proposed startup is narrower: it must own protocol-specific AR logic, missing-record retrieval, and mechanism-readout completeness.
• In-house coordinator teams. Manual chart review remains flexible, but the fetched literature shows low participation, heavy screening friction, and dependence on labor-intensive exception handling.

Series B–D oncology biotechs bringing first-in-class AR-pathway degraders into metastatic castration-resistant prostate cancer face an immediate operational bottleneck: finding the small subset of AR-driven resistant patients and generating sponsor-usable target-engagement evidence before the next board or partnering checkpoint. The current workflow is fragmented across community urology notes, pathology archives, genomic reports, biopsy scheduling, ctDNA routing, and spreadsheet follow-up, which drives slow enrollment, screen failures, and incomplete pharmacodynamic packets. This company sells a sponsor-funded workflow layer that assembles protocol-specific screening packets, retrieves missing records, and coordinates biopsy plus ctDNA evidence capture across 8–20 U.S. sites. The initial beachhead is intentionally narrow—U.S. mCRPC AR-pathway degrader studies at clinical-stage biotechs— because the buying trigger is strongest at IND clearance, site activation, and first-patient-in planning, when clinical-ops leaders need proof-of-mechanism speed more than another generic recruitment tool. Adjacent spend already exists in trial enablement, molecular profiling, site analytics, and right-in-time trial activation, so pricing can reallocate operating budget rather than invent a new AI line item. The main differentiation is sponsor-controlled AR-resistance qualification logic and cross-site mechanism-data completeness, not top-of-funnel lead volume. Two critical gaps remain unresolved in the research: it does not yet quantify the exact near-term protocol count beyond the initial buyer set, and it does not prove whether days to first qualified patient, screen-pass rate, or biomarker-packet completeness unlocks budget fastest. If early pilots show materially faster qualified enrollment and cleaner evidence packets on a repeatable template, the company can expand from prostate AR-degrader studies into broader hormone-driven and transcription-factor oncology programs; if not, it remains a services-heavy niche.

Problem

• First-in-human and early-phase mCRPC AR-pathway degrader studies require more than diagnosis matching: sponsors need prior-line treatment history, molecular resistance evidence, and serial biopsy or ctDNA plans before a patient is truly screen-ready.
• That evidence is fragmented across community urology notes, pathology archives, genomic reports, lab portals, and manual site follow-up, so the sponsor cannot reliably tell which candidates are truly eligible or which sites will produce usable mechanism data.
• Generic substitutes—manual coordinator review, CRO recruitment support, molecular-lab matching portals, and horizontal trial software—optimize pieces of the workflow but do not own sponsor-specific AR-resistance qualification plus pharmacodynamic packet completeness end to end.

Solution

• A human-in-the-loop workflow layer that ingests treatment history, genomic reports, and protocol-specific AR-resistance rules to flag likely eligible patients, retrieve missing records, and assemble sponsor-reviewed screening packets.
• Site execution tooling that schedules biopsy and ctDNA windows, routes samples to lab partners, tracks completeness, and preserves auditability so translational teams receive interpretable pharmacodynamic packets on time.
• Sponsor dashboards that benchmark referral sources, resistance profiles, screen-pass rates, and site-level biomarker completeness, allowing teams to tighten inclusion strategy while building a proprietary evidence network for future studies.

Why we win

• The company sits in the white space between recruitment vendors, CRO operations, and molecular profiling labs: a sponsor-controlled AR-resistance evidence layer spanning heterogeneous records and multiple workflow partners.
• Starting with one narrow mCRPC degrader template creates faster proof than a broad oncology recruitment product because the first buyer already has an urgent IND-to-FPI trigger and a defined evidence burden.
• Repeated deployments create a rule library linking treatment history, biomarkers, and protocol constraints, plus cross-site benchmarks on missing records, screen-pass rates, and mechanism-data completeness that generic platforms do not naturally collect.
• The company can sell with, not directly against, incumbent labs, CROs, and horizontal trial-software vendors, as long as it remains the neutral sponsor-facing orchestration layer rather than trying to replace the full trial stack.

Milestones

flowchart LR
  Wedge[AR degrader mCRPC wedge] --> MVP[Qualification plus evidence workflow MVP]
  MVP --> Proof[Faster qualified enrollment and cleaner PD packets]
  Proof --> Expansion[Adjacent hormone-driven oncology programs]

Founding team

Experiment roadmap

Risk assessment

What must be true

• At least 10 U.S. sponsor studies over the next 24 months match the beachhead profile and require serial biopsy or ctDNA evidence workflows.
• Clinical-ops buyers will sign a $150k–$250k pilot before enrollment slips, driven by IND-to-FPI pressure rather than only after a failed study start.
• Sponsors and sites will permit a third-party workflow layer to assemble prescreening packets with auditable human review and acceptable privacy and compliance controls.
• A repeatable mCRPC template can improve time to first qualified patient or screen-pass rate across multiple studies without more than 20% custom build per protocol.
• Labs, CROs, and trial networks will not fully absorb the sponsor-controlled cross-site benchmarking layer before the company reaches about 12 live studies.

Open diligence questions

• Which named sponsor protocols besides FX-111 require this workflow in the next 24 months?
• What are baseline days to first qualified patient, screen-pass rates, and biomarker-packet completeness on current manual workflows?
• Can the product operate pre-consent, or must it stay inside site-driven prescreening and post-consent workflows?
• How much of biopsy and ctDNA orchestration can be templated before gross margin falls below software-like levels?
• Would Caris, Foundation, Labcorp, or CRO partners resell this layer, or do they view it as overlap with their roadmap?

Model sanity

• Revenue engine. Revenue is driven by active studies growing from 4 at Y1 exit to 12 at Y3 exit while pricing moves from ~$200K pilot work to ~$350K recurring study-years plus support.
• Must go right. The model needs one live pilot by Month 6 and workflow reuse below the BP's 20% custom-work ceiling so gross margin can clear 70% by Y3.
• Model breaks if. If prescreening access or evidence-packet logistics stretch the sales cycle toward 9 months, the downside case falls to $2.7M Y3 revenue and cash goes negative.
• Next-round proof. A seed story exists once the pre-seed gets the company to 5 active studies, one referral channel, and setup time below four weeks before the Month-24 expansion target.

Scenarios

Sensitivity

flowchart LR
  TargetAccounts --> PaidPilots
  PaidPilots --> ActiveStudies
  ActiveStudies --> StudyRevenue
  ActiveStudies --> BenchmarkData
  BenchmarkData --> Expansion
  Expansion --> ActiveStudies
  StudyRevenue --> GrossProfit
  GrossProfit --> Cash

Flags: The researched $4.2M SOM is better read as an exit-rate framing; full-year Y3 revenue is $3.9M because the model reaches 12 live studies only in Q4Y3. · Twelve study units likely represent fewer sponsor logos than the raw count suggests, so one delayed protocol can move annualized revenue by roughly $0.3–0.4M. · Gross margin only clears 70% if custom workflow work stays below the BP's 20% threshold; otherwise the downside case requires more capital. · The model assumes the first paid pilot lands in M5 and that month-9 compliance approvals do not trigger major workflow redesign.

• Services creep. Protocol-specific biomarker workflows could make the product feel like labor-heavy trial ops instead of software. Mitigation: Start with one repeatable mCRPC workflow template around molecular pre-screening, biopsy, and ctDNA milestones, then productize the common steps across design partners.
• Site data access friction. Community urology groups and academic sites may not share treatment history and molecular data cleanly enough to surface eligible patients quickly. Mitigation: Begin with motivated GU oncology centers and referral networks, use lightweight intake connectors before full integrations, and prove conversion lift study by study.
• Adjacent vendor bundling. CROs, molecular labs, or EDC vendors could add basic enrollment and sample-tracking features once the wedge is visible. Mitigation: Win the category by owning resistance-specific qualification logic and sponsor-facing proof-of-mechanism benchmarking, while partnering with labs and CROs rather than replacing them.